Mother-Infant Transfer of Anti-Human Papillomavirus (HPV) Antibodies following Vaccination with the Quadrivalent HPV (Type 6/11/16/18) Virus-Like Particle Vaccine

Abstract

<jats:title>ABSTRACT</jats:title><jats:p>The exploratory immunogenicity objective of this analysis was to characterize the titer of vaccine human papillomavirus (HPV)-type immunoglobulins in both peripartum maternal blood and the cord blood of infants born to women who received blinded therapy. Data were derived from a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study (protocol 019; NCT00090220). This study enrolled 3,819 women between the ages of 24 and 45 years from 38 international study sites between 18 June 2004 and 30 April 2005. Data in the current analysis are from subjects enrolled in Philippines and Thailand. For each of HPV types 6, 11, 16, and 18, maternal anti-HPV was found in cord blood samples. Furthermore, HPV titers in cord blood samples were highly positively correlated with maternal HPV titers. Additionally, there were instances when anti-HPV antibodies were no longer detectable in maternal serum samples and yet were detected in matched cord blood samples. These results demonstrate that quadrivalent HPV (qHPV) vaccine-induced antibodies cross the placenta and could potentially provide some benefit against vaccine-type HPV infection and related diseases such as recurrent respiratory papillomatosis.</jats:p>

Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis

“…Vaccination against HPV could be a useful strategy in the prevention of non-oncological diseases. [9][10][11][12][13][14] It has been proposed that HPV vaccination could reduce cases of recurrent respiratory papillomatosis, both by decreasing maternal infection during pregnancy and by the passage of vaccine-induced HPV antibodies from the vaccinated mother to the fetus, 15 nevertheless this is still controversial due to lack of evidence.…”

Placental antibody transfer efficiency and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1 antibodies

“…For example, IgG transplacental transfer has been studied among preterm and term infants for certain antibodies, including tetanus, varicella, measles, and human papillomavirus (HPV). Preterm infants were found to benefit less from maternal antibodies, posing them at higher risk for infectious diseases in the first months after birth than term infants10111213. This difference may be related to the temporary decrease in total IgG during the second trimester of pregnancy due to hemodilution14.…”

The potential role of HPV vaccination in the prevention of infectious complications of pregnancy

“…They concluded that vaccination against HPV prior to pregnancy would not be effective in preventing transmission of the virus. In contrast, the results of Matys et al [26], looking at HPV titers in 3819 vaccinated women and in cord blood from their deliveries, indicate that antibodies from the qHPV vaccine could be transmitted to the fetuses/infants providing protection against transmission of HPV. Though the sample size was small, the study results seem valid since based on data from a randomized, placebo-controlled, double-blind study.…”

“…We found 11 studies [16][17][18][19][20][21][22][23][24][25][26] which addressed transmission of HPV DNA [16][17][18][19][20][21][22][23], serology in non-vaccinated pregnant women [24,25] and transmission of HPV antibodies to the placenta and/or the neonate in vaccinated pregnant women [26]. Ten of the studies are characterized in TABLES 1 and 2, respectively.…”